Sustained Health-Related Quality of Life and Work Productivity Improvements with Delgocitinib 20 Mg/G Cream in Chronic Hand Eczema-Results from the Phase 3 Open-Label Extension Delta 3 Trial
Recommended Citation
Armstrong A, Stein Gold L, Bauer A, Greig J, Norlin JM, Thoning H, Agner T. Sustained Health-Related Quality of Life and Work Productivity Improvements with Delgocitinib 20 Mg/G Cream in Chronic Hand Eczema-Results from the Phase 3 Open-Label Extension Delta 3 Trial. J Am Acad Dermatol 2026; 95(1):AB423.
Document Type
Conference Proceeding
Publication Date
7-1-2026
Publication Title
J Am Acad Dermatol
Keywords
Dermatology
Abstract
Background: Delgocitinib, a non-steroidal topical pan-JAK inhibitor for moderate to severe CHE, has been shown to improve patients’ HRQoL within 16 weeks. Methods: In the phase 3 open-label DELTA 3 (NCT04949841), patients completing the 16-week DELTA 1 and 2 trials were treated on an as-needed basis with twice-daily delgocitinib cream for an additional 36 weeks. EQ-5D-5L, Dermatology Life Quality Index (DLQI), Hand Eczema Impact Scale (HEIS) and the Work Productivity and Activity Impairment (WPAI) questionnaire were assessed over a total of 52 weeks. Data was reported as observed in patients receiving delgocitinib in the parent trials. Change from baseline in parent trials was reported in those that completed the 52 week trials. Results: Patients (n=560) had a mean age of 45.8 years (SD 14.4), and 63.4% were female. At baseline in the parent trial, average scores for EQ-5D-5L, DLQI, and HEIS were 0.64 (SD 0.23), 12.6 (6.1), and 2.49 (0.76), respectively. At end of parent trials, these scores had improved to 0.83 (0.18), 4.5 (5.0), and 0.89 (0.88), respectively. At week 36, improvements remained stable; 0.86 (0.16), 3.9 (4.1), and 0.81 (0.82), respectively. For patients who completed the study, mean improvements from baseline were significant (P< .0001): EQ-5D-5L improved by 0.20 (95% CI: 0.18, 0.22), DLQI improved by 8.5 (-9.1, -7.9), and HEIS improved by -1.66 (-1.75, -1.57). Furthermore, work productivity loss and daily activity impairment scores improved: -25.4 (-29.0, -21.9) and -33.3 (-35.8, -30.7), respectively. (P< .0001). Conclusion: Improvements in HRQoL, work productivity and daily activity impairment demonstrated after 16 weeks of continuous twice-daily treatment with delgocitinib cream were maintained after an additional 36 weeks of as-needed treatment. Acknowledgements: The DELTA 3 (NCT04949841) trial and analyses were sponsored by LEO Pharma A/S.
Volume
95
Issue
1
First Page
AB423
